for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Xencor Inc

XNCR.O

Latest Trade

34.26USD

Change

-0.57(-1.64%)

Volume

514,742

Today's Range

34.26

 - 

36.02

52 Week Range

30.12

 - 

58.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
34.83
Open
34.75
Volume
514,742
3M AVG Volume
5.28
Today's High
36.02
Today's Low
34.26
52 Week High
58.34
52 Week Low
30.12
Shares Out (MIL)
58.48
Market Cap (MIL)
2,036.91
Forward P/E
179.35
Dividend (Yield %)
--

Next Event

Q4 2021 Xencor Inc Earnings Release

Latest Developments

More

Xencor Presents Updated Data From Phase 1 Study Of Vudalimab, PD-1 X CTLA-4 Bispecific Antibody

Xencor Reports Third Quarter 2021 Financial Results And Announces Encouraging Preliminary Data From Ongoing Phase 1 Study Of Potency-Reduced Il15-FC Cytokine, Xmab306

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.

Industry

Biotechnology & Drugs

Contact Info

111 W Lemon Ave

MONROVIA, CA

91016-2809

United States

+1.626.3055900

http://www.xencor.com/

Executive Leadership

Bassil I. Dahiyat

President, Chief Executive Officer, Founder and Director

John J. Kuch

Chief Financial Officer, Senior Vice President

John R. Desjarlais

Senior Vice President, Research and Chief Scientific Officer

Allen Yang

Senior Vice President, Chief Medical Officer

Celia Eckert

Vice President, General Counsel, Corporate Secretary

Key Stats

1.85 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.2K

2020

0.1K

2021(E)

0.2K
EPS (USD)

2018

-1.310

2019

0.460

2020

-1.210

2021(E)

0.231
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.50
Price To Book (MRQ)
3.29
Price To Cash Flow (TTM)
728.77
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-0.67
Return on Equity (TTM)
-0.61

Latest News

Latest News

BRIEF-Atreca And Xencor Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

* ATRECA AND XENCOR ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES Source text for Eikon: Further company coverage:

BRIEF-Xencor And Atreca Enter Strategic Collaboration To Discover, Develop And Commercialize Novel T Cell Engaging Bispecific Antibodies

* XENCOR AND ATRECA ENTER STRATEGIC COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE NOVEL T CELL ENGAGING BISPECIFIC ANTIBODIES

BRIEF-Ecor1 Capital Reports 8.0% Passive Stake In Xencor Inc As Of June 8 - SEC Filing

* ECOR1 CAPITAL LLC REPORTS 8.0% PASSIVE STAKE IN XENCOR INC AS OF JUNE 8 - SEC FILING Source text: https://bit.ly/30Ou8Wd Further company coverage:

BRIEF-Xencor Reports Initial Dose-Escalation Data From Phase 1 Study Of XmAb 20717, PD-1 x CTLA-4 Bispecific Antibody, In Solid Tumors

* XENCOR REPORTS INITIAL DOSE-ESCALATION DATA FROM PHASE 1 STUDY OF XMAB®20717, PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN SOLID TUMORS

BRIEF-Xencor Reports First Quarter 2020 Financial Results

* Q1 EARNINGS PER SHARE ESTIMATE $-0.38 -- REFINITIV IBES DATA

BRIEF-Xencor Posts Loss Per Share Of $0.47

* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

CORRECTED-BRIEF-Marketaxess Holdings Set To Join S&P 500

* MARKETAXESS HOLDINGS SET TO JOIN S&P 500; AXON ENTERPRISE TO JOIN S&P MIDCAP 400; OTHERS TO JOIN S&P SMALLCAP 600

BRIEF-Xencor To Develop, Commercialize Il-15 Immune Activating Cytokines With Roche's Genentech

* XENCOR TO DEVELOP AND COMMERCIALIZE NOVEL IL-15 IMMUNE ACTIVATING CYTOKINES WITH GENENTECH

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up